PATENT CLAIM ANALYSIS

Application Number: 16164732
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "015200"]

Abstract:
Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

Claim (Index 2):
The method of  claim 1 , wherein the compositions are administered sequentially.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 1.32432
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15625177', '13815804', '13385528', '13998269', '13135817']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7023206710583696
- 35 USC 102 Novelty (BERT): 0.6831027152669165
- Combined Prediction Score: 0.7003988754792243
- Mean Citation Score: 510.385384
- Max Citation Score: 677.51575
- Similarity Product: 662.5494150257258

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test